More cognitive fatigue reported by patients with MS, brain injury
Adults with multiple sclerosis (MS) or traumatic brain injury report more cognitive fatigue, or exhaustion resulting from mental work,…
Articles by Margarida Maia, PhD
Telehealth intervention seen to help MS patients lose weight in trial
A six-month telehealth program designed to help participants change their dietary and lifestyle habits resulted in an increased level of…
MS also less common among men in China, but more disabling
Fewer men than women are diagnosed with multiple sclerosis (MS) in China — as elsewhere — but more male…
US neurologists favorably view BTK inhibitors as potential MS therapies
More than one-third of neurologists in the U.S. believe Bruton’s tyrosine kinase (BTK) inhibitors could be of pivotal significance as…
Ginger eases digestive symptoms in RRMS patients: Trial data
Taking a ginger supplement eased constipation, nausea, bloating, and abdominal pain in people with relapsing-remitting multiple sclerosis (RRMS) who…
5 conditions MS patients may have years before diagnosis ID’d: Study
People with multiple sclerosis (MS) are more likely to experience depression, sexual dysfunction, constipation, inflammation of the bladder, and urinary…
Quality of life gains with Mavenclad sustained for 2 years: Phase 4 trial
Treatment with Mavenclad (cladribine) over two years significantly improved physical and mental health aspects of quality of life in…
With younger age at PPMS onset, higher disease activity can be seen
People with primary progressive multiple sclerosis (PPMS) at younger ages are more likely to have higher disease activity, suggesting…
New US patent likely to cover all vidofludimus calcium doses in MS
The Patent and Trademark Office intends to grant a U.S. patent covering all dosing regimens of vidofludimus calcium —…
COVID-19 not linked to increased MS relapse rate: Meta-analysis
COVID-19 doesn’t appear to increase the likelihood of a relapse, where new symptoms suddenly appear or existing ones worsen, for…
Study ties central neuropathic pain to more severe emotional burden
Central neuropathic pain — the kind resulting from damage to the brain and spinal cord — appears to be more…
High DMT adherence lowers risk of moderate or severe relapse by 25%
A high level of adherence to disease-modifying therapies (DMTs) is associated with a significant, 25% lower risk of moderate…
US patent likely for vidofludimus calcium at relapsing MS trial dose
Immunic Therapeutics has been notified of the intent to grant a U.S. patent covering the use vidofludimus…
Saffron supplement, exercise combo may ease depression in MS women
Combining a saffron supplement and an exercise program for three months was seen to significantly ease depression and improve quality…
Neural Sleeve to aid walking with MS makes Time’s best inventions list
Neural Sleeve, a bionic piece of clothing by Cionic designed to help with walking and strength, is among…
Low vitamin D blood levels tied to poorer cognition, greater disability
Low blood levels of vitamin D are tied to poorer cognitive skills and more severe disability in people with…
Greater income, education before diagnosis linked to less severe MS
Socioeconomic factors, specifically income and education levels, and marital status, were identified as risk factors for multiple sclerosis (MS) severity…
PML caused by Tysabri results in lasting neurological symptoms
People with multiple sclerosis (MS) who develop progressive multifocal leukoencephalopathy (PML)Â as a side effect of Tysabri (natalizumab) often…
Mental health can trouble MS patients 5 years before diagnosis
Anxiety, depression, and other mental health issues are nearly twice as common in people with multiple sclerosis (MS) in…
How well MS patients adhere to treatment tied to certain factors
People with multiple sclerosis (MS) who experience a greater number of more severe flare-ups, also known as relapses, are…
Brain volume loss helps in judging DMT efficacy in RRMS: Review
The rate of brain atrophy, or volume loss, may help in determining whether disease-modifying therapies (DMTs) are slowing disability…
COVID-19 vaccines safe, do not worsen MS symptoms: Study
Certain COVID-19 vaccines do not appear to worsen the symptoms of multiple sclerosis (MS), and may provide protection for…
MS patients with Shields Health Solutions have $10 copay for care
People with multiple sclerosis (MS) in the U.S. who have access to a Shields Health Solutions care model…
MS Australia awards incubator grants to four research projects
Four researchers working in multiple sclerosis (MS) were awarded incubator grants in MS Australia’s latest funding round, which…
Using highly effective DMTs early linked to fewer relapses in children
Children and adolescents with multiple sclerosis (MS) who receive high-efficacy disease-modifying therapies (DMTs) early on are significantly less…
EMBOLD data covering over 90 MS patients now due in November
Atara Biotherapeutics now is planning to announce in November the one-year data from its EMBOLD Phase 1/2 study, which…
Gilenya generic safe and effective, adherence good: Real-world study
A generic equivalent of oral Gilenya (fingolimod) significantly lowers relapse rates, slows disability progression, and works against new lesions…
Using Copaxone while breastfeeding safe for infants: Study
Infants breastfed by mothers on Copaxone (glatiramer acetate) for relapsing forms of multiple sclerosis (MS) do not experience…
Early disability tied to higher risk of secondary progressive MS: Study
Experiencing disability in the early stages of multiple sclerosis (MS), even without relapses, increases the risk of progression to…
Adhering to treatment is linked to better long-term outcomes
People with multiple sclerosis (MS) who take their prescribed disease-modifying therapies (DMTs) as recommended have better long-term health…